PLYMOUTH, Minn.--(BUSINESS WIRE)--Uromedica, Inc., today announced that it has successfully completed its first US commercial implant of ProACT™ Adjustable Continence Therapy for Men. The procedure ...

MINNEAPOLIS--(BUSINESS WIRE)--Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI.

June 2, 2010 (San Francisco) – An investigational minimally invasive device, known as the Adjustable Continence Therapy (ACT, Uromedica, Inc.) system, seems to be an effective treatment for women with ...

Preliminary results from the North American Adjustable Continence Therapy (ACT) clinical study group will be presented at the annual meeting of the American Urological Association convened in Anaheim, ...

Introduction and Objectives: The efficacy of adjuvant and salvage external beam radiation (AXRT+SXRT) for prostate cancer after radical prostatectomy (RP) has been debated because of the inability to ...